Package Leaflet: Information for the User
Ticagrelor Tarbis 60 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
What is Ticagrelor Tarbis
Ticagrelor Tarbis contains the active substance ticagrelor. It belongs to a group of medicines called antiplatelet agents.
What Ticagrelor Tarbis is used for
Ticagrelor in combination with acetylsalicylic acid (another antiplatelet agent) should only be used in adults. You have been prescribed this medicine because you have had:
This medicine reduces the risk of you having another heart attack, a stroke, or dying from a heart or blood vessel disease.
How Ticagrelor Tarbis works
Ticagrelor works on cells called ‘platelets’ (also called thrombocytes). These very small blood cells help stop bleeding by clumping together to block small holes in blood vessels that are cut or damaged.
However, platelets can also form clots inside damaged blood vessels in the heart and brain. This can be very dangerous because:
Ticagrelor helps prevent platelets from clumping together. This reduces the chance of a blood clot forming that could reduce blood flow.
Do not take Ticagrelor Tarbis if:
Do not take Ticagrelor if you are in any of the above situations. If you are unsure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before taking this medicine if:
If any of the above applies to you (or if you are unsure), consult your doctor or pharmacist before taking this medicine.
If you are taking Ticagrelor and heparin:
Children and adolescents
Ticagrelor is not recommended for children and adolescents under 18 years of age.
Other medicines and Ticagrelor Tarbis
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. This is because Ticagrelor may affect the way some medicines work and some medicines may affect Ticagrelor.
Tell your doctor or pharmacist if you are taking any of the following medicines:
In particular, tell your doctor or pharmacist if you are taking any of the following medicines that increase the risk of bleeding:
Tell your doctor that, because you are taking Ticagrelor, you may have a higher risk of bleeding if your doctor gives you fibrinolytics, often referred to as ‘clot dissolvers’, such as streptokinase or alteplase.
Pregnancy and breastfeeding
Ticagrelor should not be used if you are pregnant or may become pregnant. Women should use appropriate contraceptive methods to avoid pregnancy while taking this medicine.
Consult your doctor before taking this medicine if you are breastfeeding. Your doctor will explain the benefits and risks of taking this medicine during this period.
If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.
Driving and using machines
Ticagrelor is unlikely to affect your ability to drive or use machines. If you feel dizzy or confused while taking this medicine, be careful while driving or using machines.
Ticagrelor Tarbis contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. If you are unsure, consult your doctor or pharmacist.
How much to take
Taking Ticagrelor Tarbis with other blood clotting medicines
Your doctor will also usually prescribe acetylsalicylic acid. This is a substance found in many medicines used to prevent blood clotting. Your doctor will tell you how much to take (usually between 75-150 mg daily).
How to take Ticagrelor Tarbis
If you have difficulty swallowing the tablet
If you have difficulty swallowing the tablet, you can crush it and mix it with water as follows:
If you are in the hospital, this tablet may be given to you mixed with a little water through a tube in your nose (nasogastric tube).
If you take more Ticagrelor Tarbis than you should
If you take more Ticagrelor than you should, consult your doctor or go to the hospital immediately. Bring the medicine pack with you. You may have a higher risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Ticagrelor Tarbis
If you stop taking Ticagrelor Tarbis
Do not stop taking this medicine without consulting your doctor. Take this medicine regularly and for as long as your doctor recommends. If you stop taking Ticagrelor, you may increase the risk of having another heart attack or stroke or dying from a heart or blood vessel disease.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. With this medicine, the following side effects may occur:
Ticagrelor affects blood clotting, so most side effects are related to bleeding. Bleeding can occur anywhere in the body. Some level of bleeding is common (such as bruising and nosebleeds). Severe bleeding is uncommon but can be life-threatening.
Tell your doctor immediately if you notice any of the following - you may need urgent medical treatment:
Tell your doctor if you notice any of the following:
Other possible side effects
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Frequency not known(cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Ticagrelor Tarbis
The active ingredient is ticagrelor.
Each film-coated tablet contains 60 mg of ticagrelor.
The other ingredients are:
Tablet core: Mannitol (E421), sodium carboxymethyl starch (Type A) from potato, povidone K-30 (E1201), microcrystalline cellulose, magnesium stearate (E470b).
Coating: Hypromellose (E464), macrogol 400 (E1521), macrogol 6000 (E1521), talc (E553b), titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172).
Appearance and Packaging of the Product
Film-coated tablets, biconvex, round in shape, peach to light brown in color, with an approximate diameter of 8.05 mm, engraved with "68" on one side and "V1" on the other.
Ticagrelor Tarbis is available in blisters containing 14, 50, 56, 60, 100, and 168 film-coated tablets and HDPE bottles containing 60 and 180 film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Tarbis Farma S.L.
Gran Vía Carlos III, 94
08028 Barcelona
Spain
Manufacturer
Amarox Pharma B.V.
Rouboslaan 32
Voorschoten, 2252TR
Netherlands
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Germany: Ticagrelor Amarox 60 mg Filmtabletten
Netherlands: Ticagrelor Amarox 60 mg, filmomhulde tabletten
Spain: Ticagrelor Tarbis 60 mg film-coated tablets EFG
Date of the last revision of this leaflet: January 2025
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.